Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer
Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer
复制标题
DOI：
10.1002/ijc.25200
复制
发表时间：
2010-10-15
影响因子：
6.4
通讯作者：
Itoh, Yoshinori
中科院分区：
文献类型：
--
作者：
Watanabe, Tomoko;Ishihara, Masashi;Itoh, Yoshinori
口腔粘膜炎是头颈部癌症放疗或放化疗的常见但严重的不良事件，严重损害健康相关的生活质量，导致预后不良，因为停止治疗。虽然已经测试了许多化合物用于预防口腔粘膜炎，但它们中很少有令人满意的。我们研究了胃粘膜保护药物polaprezinc（L-肌肽锌）对头颈癌患者放疗引起的口腔粘膜炎、疼痛、口干和味觉障碍的影响。患者被随机分配接受polaprezinc（n = 16）或作为对照组（n = 15）的甘菊环口腔冲洗。治疗组口腔黏膜炎、疼痛、口干和味觉障碍的发生率均明显低于对照组。此外，与对照组相比，Polaprezinc组镇痛药的使用频率显著降低（p = 0.003），摄食量显著增加（p = 0.002）。另一方面，新辅助放化疗患者的肿瘤缓解率未受到Polaprezinc的显著影响，其中Polaprezinc的缓解率（完全缓解加部分缓解）为88%，对照组为92%（p = 1.000）。因此，高度肯定的是，Polaprezinc可用于预防口腔粘膜炎和改善生活质量，而不会降低肿瘤反应。
Oral mucositis is frequent but serious adverse event associated with radiotherapy or radiochemotherapy in head and neck cancer severely impairs health-related quality of life, leading to poor prognosis due to discontinuation of the therapy. Although a number of compounds have been tested for prophylaxis of oral mucositis, few of them are satisfactory. We investigated the effect of polaprezinc (zinc L-carnosine), a gastric mucosal protective drug, on radiochemotherapy-induced oral mucositis, pain, xerostomia and taste disturbance in patients with head and neck cancer. Patients were randomly assigned to receive polaprezinc (n = 16) or azulene oral rinse as the control (n = 15). The incidence rates of mucositis, pain, xerostomia and taste disturbance were all markedly lower in polaprezinc group than in control. Moreover, the use of analgesics was significantly (p = 0.003) less frequent and the amount of food intake was significantly (p = 0.002) higher in polaprezinc group than in control. On the other hand, tumor response rate in patients with neoadjuvant radiochemotherapy was not significantly affected by polaprezinc, in which the response rate (complete plus partial response) was 88% for polaprezinc and 92% for control (p = 1.000). Therefore, it is highly assumable that polaprezinc is potentially useful for prevention of oral mucositis and improvement of quality of life without reducing the tumor response.